Description
CS5 is described as a fixed blend of cagrilintide 2.5 mg and semaglutide 2.5 mg. This combination is investigational and is not an FDA-approved finished drug product in the United States.
CS5 is described as a fixed blend of cagrilintide 2.5 mg and semaglutide 2.5 mg. This combination is investigational and is not an FDA-approved finished drug product in the United States.
CS5 is described as a fixed blend of cagrilintide 2.5 mg and semaglutide 2.5 mg. This combination is investigational and is not an FDA-approved finished drug product in the United States.
| Quantity | 5mg |
|---|
Reviews
There are no reviews yet.